好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Treatment of Unruptured Intracranial Aneurysms in the Pediatric Population
Interventional Neurology
P04 - (-)
083
BACKGROUND: Previous studies have thoroughly examined treatment options for intracranial aneurysms in the adult population. However, similar studies have not been performed within the pediatric population.
DESIGN/METHODS: We analyzed the data obtained as part of the Kids' Inpatient Database between 2003 and 2009 with primary diagnosis of UIA (identified by the International Classification of Disease, Ninth Revision). Patients undergoing endovascular coiling were compared to those undergoing microsurgical clipping. Outcomes were defined as rates of intracerebral hemorrhage (ICH), in-hospital mortality, or favorable outcome (discharge disposition of home/self-care).
RESULTS: From 2003 to 2009, there were 818 cases of UIAs. A total of 188 patients (mean age 13卤8 years, 43% female) underwent coiling, and 123 patients (mean age 14卤6 years, 36% female) underwent clipping for UIAs. The rate of ICH was similar between coiling and clipping patients (2.1% vs 5%, p=0.3). There was no mortality among those who underwent clipping, but there were 3 patients who underwent coiling that suffered in-house mortality (p=0.28). A large number of patients undergoing either treatment experienced a favorable outcome after treatment (91% coiling, 89% clipping, p=0.6).
CONCLUSIONS: Treatment and associated outcomes of UIAs in pediatric population remains under studied. Prospective studies are needed to identify the natural history and best treatment strategies in this patient population with UIAs.
Authors/Disclosures
Ganesh Asaithambi, MD, FAAN (Allina Health Neuroscience Institute)
PRESENTER 		Dr. Asaithambi has nothing to disclose.
No disclosure on file
Hamza I. Maqsood, MD (Dept of Neurology) Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.
Michael S. Okun, MD, FAAN (University of Florida) Dr. Okun has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Okun has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Parkinson's Foundation. Dr. Okun has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Okun has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Journal Watch. The institution of Dr. Okun has received research support from NIH. The institution of Dr. Okun has received research support from Parkinson's Foundation. The institution of Dr. Okun has received research support from Tourette Association of America. The institution of Dr. Okun has received research support from Michael J Fox. Dr. Okun has received publishing royalties from a publication relating to health care.